Medtech Investors

What are Medtech investors, and what do they look for?

Device investors work backwards from the regulatory class, because that single classification determines cost, timeline and whether the company is fundable on the capital available. A low-risk device with an established predicate reaches market on modest money. A high-risk implantable requires clinical investigation, notified body assessment and years of work before revenue exists. Founders who have not established their class with proper advice are asking investors to underwrite an unknown. Clinical evidence is the second pillar and the one European rules have made heavier. Buyers and regulators now expect data demonstrating that the device performs as claimed and is safe in real use, and generating it takes time and money that must be in the plan. Reimbursement is the third and most frequently underestimated. A device that works, is approved and has no reimbursement code is a product hospitals admire and do not buy. Investors want to know which payment mechanism applies in which countries and what precedent exists. Finally, manufacturing and quality systems. Devices require controlled production, traceability and post-market surveillance, and building that infrastructure is a substantial programme rather than an operational detail.

Why Medtech is attracting investor interest

Europe's medical device rules were rewritten, and the consequences reshaped the market in ways investors are still working through. The current framework raised evidence requirements, tightened conformity assessment and created a bottleneck in notified body capacity. Established manufacturers withdrew products rather than recertify them, which left gaps in the market that newer companies can occupy. That disruption cuts both ways and investors are candid about it. Compliance costs more and takes longer, which raises the capital required. It also weakens the incumbent advantage, since everyone had to requalify, and a well-prepared new entrant faces a less protected field than it would have a decade ago. Clinical need continues to grow independently of any of this. Ageing populations, surgical backlogs and workforce shortages across European health systems create demand for devices that shorten procedures, move care out of hospitals or let fewer staff treat more patients. Software as a medical device has become its own category, drawing investors who understand software economics into a regulated environment. The economics are attractive once approved, since distribution costs little, though the approval work is real.

Which funding stages Medtech investors are active at

Medtech stages track regulatory and evidence milestones rather than revenue, which makes the vocabulary unfamiliar to software investors. Seed funds prototype development, early bench testing and a regulatory strategy. Investors weigh clinical founder involvement heavily, since a device designed without practitioners tends to fail on usability regardless of its engineering. Series A funds the clinical and regulatory programme, and is typically sized to reach conformity assessment or a first approval. This is where companies most often run short, because notified body timelines have been unpredictable and founders budgeted for the process they expected rather than the one that exists. Series B funds commercial launch, which in European healthcare means hospital procurement, tender processes and reference-selling between institutions. Investors examine whether the second hospital took less effort than the first. Later rounds are frequently strategic. Established device manufacturers acquire regularly, and many European medtech outcomes are trade sales rather than independent scaling. Growth investors specialising in medical technology exist but are fewer than in software, so mapping them early is worthwhile.

Typical check and round sizes in Medtech

Sector averages would mislead here because regulatory class drives capital requirements more than product ambition does, and the classes differ by orders of magnitude. The framing that helps is to size each round against a regulatory or evidence milestone and to name it explicitly. Investors underwrite the milestone, so a raise described in months of runway rather than in approvals achieved suggests unfamiliarity with how the sector funds itself. Build genuine contingency into clinical and certification timelines. Notified body capacity constraints have produced delays outside any company's control, and a round sized with no margin converts an external delay into a financing crisis. Investors who know the sector will apply their own buffer, so showing that you have already applied one is the way to avoid being repriced. Quality management systems and post-market surveillance are ongoing costs rather than one-off projects, and they scale with product range. Founders frequently omit them from projections and are corrected during diligence. Non-dilutive funding is available across Europe for medical device development and clinical studies, and it suits the evidence-generation stage that equity investors are least enthusiastic about funding. For comparables, use recent European rounds from companies in the same regulatory class addressing similar clinical areas.

Types of investors active in Medtech

What Medtech investors look for in diligence

Medtech diligence brings clinical and regulatory specialists into the process, and they read your documentation rather than your summary of it. Regulatory classification is verified independently. Investors will ask which rule you classified under, who advised you, and whether a notified body has agreed. An optimistic classification that a reviewer disputes can reset the entire plan, so this is checked early and carefully. Clinical evidence is assessed for adequacy against the claims being made. Study design, endpoints, comparator, sample size and whether the evidence supports the intended use as written. Investors are alert to studies that demonstrate something adjacent to the claim rather than the claim itself. Quality management systems are examined as operating functions, including design controls, traceability, supplier management and post-market surveillance. A company without a functioning system cannot legally place a product on the market, so this is not a formality. Reimbursement pathway analysis covers which codes apply, in which countries, what tariff attaches and whether comparable devices have secured payment. Manufacturing readiness is reviewed, including whether contract manufacturers are qualified and whether the supply chain supports the volumes projected. Intellectual property receives the usual scrutiny, with particular attention to freedom to operate, since device fields are often crowded with existing patents held by large incumbents who defend them.

How to build a fundraising strategy as a Medtech startup

Establish your regulatory classification early and document the advice behind it. It is the foundation of the entire plan, and investors treat a well-evidenced classification as a signal of general seriousness. Guessing, or classifying optimistically, undermines everything downstream. Plan the clinical evidence programme as the main event rather than a supporting task. It is usually the largest pre-revenue cost, the longest pole in the timeline, and the thing that determines whether hospitals will buy. Founders who present a credible evidence plan with named investigators and realistic recruitment estimates stand out immediately. Use non-dilutive funding for studies. Public and charitable funding across Europe supports clinical validation, and arriving at Series A having spent grant money instead of equity leaves founders with a materially larger share of the company. Involve clinicians from the beginning, on the team, the advisory board or the cap table. Devices designed without practitioner input fail on workflow, and investors have seen enough of it to check. Work out reimbursement before commercial launch, not after. Approval and reimbursement are separate processes with separate timelines, and a device with the first and not the second has no route to volume. Sequence European markets deliberately. Health systems differ enough in procurement and payment that success in one is limited evidence for the next, and a plan naming two specific markets with reasoning beats one that treats Europe as a single opportunity.

Common mistakes founders make raising Medtech capital

Classifying a device optimistically to avoid a harder regulatory route is the most damaging error, and it surfaces during diligence when a specialist disagrees. The resulting reset costs years, and the judgement error colours everything else investors assess. Underestimating notified body timelines has become a defining problem for European medtech. Capacity constraints have produced delays that companies could not have shortened, and plans built on optimistic assumptions ran out of money waiting. Treating reimbursement as a commercial detail rather than a strategic milestone leaves companies with approved products nobody will pay for. This is the most common reason a technically successful device fails commercially in Europe. Designing without clinicians produces devices that work in testing and irritate in practice. Adoption in healthcare depends on fitting an existing workflow, and practitioners abandon products that add steps. Skimping on quality systems creates a problem that compounds. Post-market surveillance and traceability obligations are continuing, and companies that treat them as launch paperwork face remediation later at much greater cost. Assuming European approval opens all European markets is a persistent misunderstanding. Regulatory approval is one gate; procurement, reimbursement and clinical acceptance are separate ones that operate country by country.

How Medtech investment differs across Europe

Germany has the largest medical device market in Europe and a substantial domestic manufacturing base, with strong regional clusters in device engineering. Hospital procurement is structured and evidence-driven, and a German reference customer carries weight across the continent. Switzerland has exceptional precision manufacturing capability and a dense medical technology sector, alongside proximity to large device and pharmaceutical groups. Its position outside the European Union adds regulatory complexity for market access that companies there must plan around. Ireland hosts significant medical device manufacturing for international groups, which makes it strong on production capability and supply chain access rather than on early-stage device innovation. The UK has excellent clinical research infrastructure and a large single health system, which simplifies evidence generation and complicates procurement, since national-level adoption decisions are slow but comprehensive when they arrive. The Nordics combine high-quality clinical data infrastructure with health systems that are comparatively willing to trial new approaches, making them efficient markets for evidence generation. France provides substantial public support for health technology and a large hospital network, with adoption typically progressing through regional structures rather than nationally. The Netherlands and Belgium hold dense medical technology clusters backed by strong translational support, and companies frequently base European operations there whatever the origin of the technology.